Organization
Clarity Pharmaceuticals
Aliases
Clarity Pharmaceuticals Ltd
9 clinical trials
2 abstracts
Clinical trial
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Positron Emission Tomography Imaging of Participants With Known or Suspected Neuroendocrine Tumours Using 64Cu SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II StudyStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical TrialStatus: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Phase I/IIa Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance StudyStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 1/2 Study of Participants With Biochemical Recurrence of Prostate CancerStatus: Completed, Estimated PCD: 2023-08-08
Clinical trial
64Cu-SAR-BBN Positron Emission Tomography: A Phase 2 Study of Participants With PSMA-negative Biochemical Recurrence of Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Positron Emission Tomography Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: A Multi-Centre, Blinded Review, Dose Ranging Phase I StudyStatus: Completed, Estimated PCD: 2022-10-19
Abstract
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.Org: Mayo Clinic Rochester, Rochester, MN, Clarity Pharmaceuticals, XCancer Omaha, Omaha, NE, Washington University in St. Louis, Mayo Clinic,
Abstract
64Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.Org: Clarity Pharmaceuticals, Eveleigh, Nepean Hospital, GenesisCare, Fort Myers, FL, Department of Theranostics and Nuclear Medicine,
Clinical trial
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance StudyStatus: Recruiting, Estimated PCD: 2025-02-01